At what enterprise value was MEDIPASS acquired in 2020?

During the acquisition of MEDIPASS by DWS GROUP in 2020, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of MEDIPASS when it was acquired by DWS GROUP?

The estimated EV/EBITDA multiple for MEDIPASS is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was MEDIPASS acquired by DWS GROUP?

MEDIPASS was acquired by DWS GROUP in 2020.

What was the revenue of MEDIPASS at the time of the deal?

The revenue of MEDIPASS at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of MEDIPASS during the acquisition?

MEDIPASS's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the MEDIPASS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MEDIPASS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://bebeez.eu/2020/09/08/inframedica-dws-to-buy-medipass-in-a-1692-mln-euros-deal-from-italys-kos-which-is-lowering-its-debt-by-160-mln/

← DATABASE

Home Database Healthcare & PharmaMEDIPASS

11/2020

MEDIPASS acquired by DWS GROUP

ITALY Health Providers / Outpatient Care / Radiology EV 100M - 350M EUR

Context

DWS Alternatives Global Limited has acquired 100% of Medipass srl, a leading provider of cancer care and advanced diagnostic imaging services in Italy and the United Kingdom.

MEDIPASS, which reported an EBITDA margin of in 2017, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Medipass is a leading Italian provider of outsourced medical imaging, nuclear medicine, and advanced radiotherapy services for both public and private healthcare institutions. Headquartered in San Giovanni in Persiceto (Bologna), the company operates through a specialized B2B business model, managing complex diagnostic departments directly within hospitals (in-situ) or via a network of independent diagnostic clinics. Its core value proposition focuses on high-tech clinical outsourcing, encompassing technology procurement, specialized architectural design, medical physics, and ongoing technical operations for advanced equipment like MRI, CT, and PET-CT scanners.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2017

2016

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2020	RADIOLOGY PARTNERS	MEDNAX RADIOLOGY SOLUTIONS	UNITED STATES	Radiology
12/2020	ANTIN INFRASTRUCTURE	HIPPOCRATES (LAF - LA FARMACIA)	ITALY	Pharmacy
11/2020	APHEON (EX ERGON)	VIDACURA	GERMANY	Nursing Homes
11/2020	ARDIAN	INOVIE GROUP	FRANCE	Labs (Biology)
11/2020	MEDICA GROUP	GLOBAL DIAGNOSTICS	IRELAND	Radiology
11/2020	L CATTERTON	ALLIANCE ANIMAL HEALTH	UNITED STATES	Vet Clinics
10/2020	KKR / TETHYS INVEST / ARDIAN / CNP ASSURANCES / MERIEUX EQUITY PARTNERS	ELSAN	FRANCE	Clinics / Hospitals
10/2020	THE VISTRIA GROUP / CENTERBRIDGE PARTNERS	HELP AT HOME	UNITED STATES	Nursing Homes
10/2020	INFRATIL	QSCAN GROUP	AUSTRALIA	Radiology
09/2020	EQT PARTNERS	COLISÉE	FRANCE	Nursing Homes

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MEDIPASS by DWS GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: medipass

Acquirer: dws group